Marksans Pharma Limited — Investor Meet, 25-11-2024: Analysts/Institutional Investor Meet/Con. Call Updates

1. **Financial Performance**: Marksans Pharma reported a robust operating revenue of INR 641.9 crores for Q2 FY25, reflecting a year-on-year growth of 20.8%. The US market was a standout, contributing INR 304.2 crores, up 36.8% year-on-year, aided by new product launches. Gross profit surged to INR 383.5 crores, resulting in a gross margin expansion of 732 basis points to 59.7%. EBITDA reached an all-time high of INR 135.7 crores with a 19.1% increase, while profit after tax rose to INR 97.8 crores, marking a 16.6% growth. For H1 FY25, total revenue reached INR 1,232.5 crores, a 19.5% increase from last year.

2. **Future Outlook and Growth Drivers**: Management expressed optimism about growth, particularly with a focus on expanding the US business and new product launches. The Teva facility is expected to ramp up, enhancing operational capacity and supporting anticipated revenue growth towards the target of INR 3,000 crores in the next two years.

3. **Order Book and Operational Updates**: The order book stands at $200 million. The Teva facility, currently operating at about 40% capacity, generated approximately INR 100 crores in revenue this quarter, with expectations for further growth as operations scale up.

4. **Analyst Q&A Insights**:

- **Revenue and Profitability**: Analysts inquired about the growth drivers, with management indicating strong new product introductions and market share gains as key factors.

- **Market Position and Competitive Landscape**: There was discussion about the competitive dynamics in the US and UK markets, with management maintaining that both regions are priorities but expect seasonal fluctuations in performance.

- **Operational Challenges or Risks**: While acknowledging ongoing supply chain challenges and freight cost fluctuations, management remains confident in mitigating these risks.

- **Capex and Capital Allocation**: Plans for further investments were discussed, particularly in enhancing manufacturing capabilities beyond the Teva facility.

- **Strategic Priorities and Long-Term Vision**: Analysts probed management’s long-term vision, which aims for continuous growth and market leadership in targeted geographies.

5. **Market or Regulatory Updates**: No significant regulatory updates were mentioned, but the company’s strategies are aligned with cautious optimism regarding market stability.

6. **Strategic Focus Areas**: Key themes included a commitment to innovation and product expansion, particularly in underserved markets like Australia and Europe, reflecting a positive management tone about growth opportunities.

7. **Investor Insight**: Given the strong financial performance, growth trajectory, and strategic positioning, the company appears poised for future growth, suggesting a favorable outlook for investors.